Trials / Unknown
UnknownNCT04817527
Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows
Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows (EXISTENT):a Prospective, Randomized, Open-label, Multi-centre Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To explore the safety and efficacy of edaravone dexborneol for patients of acute ischemic stroke received endovascular therapy in extended time windows.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Edaravone Dexborneol | Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days. |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-31
- First posted
- 2021-03-26
- Last updated
- 2022-04-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04817527. Inclusion in this directory is not an endorsement.